The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.
The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.
Swiss generic drugmaker Sandoz has reached a settlement agreement to pay $450 million to 43 US states and territories to resolve antitrust litigation alleging anti-competitive conduct and price manipulation in the generic medicines market. The settlement includes no admission of wrongdoing and will not affect the company's financial guidance.
The Supreme Court heard oral arguments on a case involving 'skinny labeling' practices that have significant implications for generic drug availability and access, with justices appearing to signal the practice may survive legal challenge.
The FDA approved Ranluspec as the first interchangeable ranibizumab biosimilar, Biocon launched denosumab biosimilars Bosaya and Aukelso in the US, and Celltrion's Truxima became the first Korean biosimilar to lead its segment in US prescriptions.
President Donald Trump announced that imported generic drugs will face no tariffs for two years starting August 1, 2026, after which tariffs will rise to 100% in August 2028 and 200% from 2029 onward. The policy aims to encourage domestic pharmaceutical manufacturing but raises concerns about future drug price increases for consumers.
